All the trials using tofacitinib for maintenance of remission in UC have allowed the use of concomitant therapies except glucocorticoids. Mesalamine, a drug used in mild-to-moderate UC is often continued in patients receiving other drugs for maintenance. In this study, we plan to compare the effect of withdrawing mesalamine and continuing monotherapy with tofacitinib versus continuing dual therapy with tofacitinib and mesalamine. We hypothesize that the continuation of tofacitinib monotherapy after withdrawing mesalamine will be as efficacious and safe as continuation of the combination in remission maintenance in UC.
Diagnosed cases of UC by endoscopy and biopsy
Patients in clinical remission for at least 3 months on Tofacitinib and mesalamine
Incomplete evaluation
Uncertain diagnosis
Active disease
Subjects with Crohn's disease, microscopic colitis and collegenous colitis or IBD-U